Short answer
Bausch & Lomb Corp (BLCO) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item 1.01 (Entry into a Material Definitive Agreement). Item 1.01 points to the Ross Agreement disclosure under Item 5.02.
Bausch & Lomb Corp 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Item 1.01 points to the Ross Agreement disclosure under Item 5.02
- Investor focus: agreement terms and obligations depend on the referenced executive-change disclosure
Item 5.02 · Departure/Election of Directors or Officers
- Four directors resigned August 5, 2026, replaced at controlling shareholder BHC’s request
- BHC CEO Thomas Appio joined the board, increasing direct representation of the controlling shareholder
- Three new directors deemed independent, but committee assignments and lead independent director remain undecided
- Departing directors received prorated compensation and accelerated vesting of 2026 restricted stock units
- Former director Thomas Ross retained as consultant for one year at $400,000, payable in four $100,000 installments
Item 8.01 · Other Events
- August 6, 2026 press release announces a Board update
- Exhibit 99.1 includes financial information for quarter ended June 30, 2026
- Board changes may affect governance, oversight and strategic direction
Item EX-99.1 · Exhibit EX-99.1
- Board overhaul at majority owner Bausch Health’s request, with four new directors replacing four resignations
- Bausch Health controls approximately 87% of outstanding shares, reinforcing majority-owner influence over governance
- Second-quarter revenue $1.394B, up 9% reported and 8% constant currency, with Surgical and Pharmaceuticals growing double digits
- Operating cash flow rose to $153M from $32M in Q1; adjusted cash flow reached $161M from $45M
- 2026 guidance reaffirmed: revenue $5.440B-$5.540B and adjusted EBITDA excluding Acquired IPR&D $1.025B-$1.075B
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Bausch & Lomb Corp 8-K filings
Get the next BLCO 8-K as it lands
Follow BLCO for push alerts, or ask the research agent what this filing means.